Glaucoma supplement trial fizzles: MEMOPTIC study halted early

NCT ID NCT04499157

Terminated Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily tablet called MEMOPTIC (containing citicoline, magnesium, and Ginkgo biloba) could help preserve vision in people with open-angle glaucoma when added to their usual eye-pressure-lowering treatments. The trial planned to follow 15 patients for two years, but it was terminated early. Because of the small size and early stop, no firm conclusions can be drawn about whether MEMOPTIC helps protect vision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MEMOPTIC (a tablet combining citicoline, magnesium, and Ginkgo biloba)
What this could lead to: If it worked, MEMOPTIC might help preserve vision in glaucoma patients when added to standard pressure-lowering treatments.
What could go wrong: The trial was terminated early and included only 15 people, so results are very limited. It is unclear if the supplement provides any real benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPEN-ANGLE GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPEN-ANGLE GLAUCOMA VISUAL FIELD

Contacts and locations

Locations

CHU Amiens

Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.